HSBC is bullish on Biopharma stocks
HSBC analysts initiated research coverage of Biopharma stocks with a predominantly positive view. The analysts argue that “a loss of exclusivity and drug pricing regulations are likely to...
HSBC analysts initiated research coverage of Biopharma stocks with a predominantly positive view. The analysts argue that “a loss of exclusivity and drug pricing regulations are likely to...
An analyst from HSBC initiated coverage of Moderna (NASDAQ: MRNA) at 'reduce' with a price target of $97.00. Prior to this rating, Moderna had 10 buy ratings, 9 hold ratings, and 1 sell...
An analyst from Morgan Stanley maintained Moderna (NASDAQ: MRNA) at 'equalweight' with a price target of $128.00 from a prior price target of %currency%%price%. Prior to this rating,...
By Yasin Ebrahim Investing.com -- The Dow closed lower Wednesday, as the Federal Reserve’s minutes from its June meeting showed further appetite to resume hikes, though big tech was...
By Bansari Mayur Kamdar and Johann M Cherian (Reuters) - Wall Street's main indexes fell on Wednesday ahead of the Federal Reserve's June meeting minutes, while weak U.S. and China economic...
Investing.com -- U.S. stocks were falling as investors awaited the minutes of the latest Federal Reserve policy meeting. At 9:39 ET (13:39 GMT), the Dow Jones Industrial Average was down 140...
(Updated - July 5, 2023 9:39 AM EDT) Moderna (NASDAQ:MRNA) Climbs 5%Earlier: Moderna (MRNA) Announces Global Regulatory Submissions For MRNA-1345Earlier: Moderna to invest $1 billion...
Investing.com -- Shares in Moderna (NASDAQ:MRNA) moved higher on Wednesday after media reports said that the drugmaker had signed a memorandum of understanding and a land collaboration...
Moderna (NASDAQ:MRNA) has submitted marketing authorization applications for the investigational RSV vaccine, mRNA-1345, with the European Medicines Agency, Swissmedic, and the...
The filing follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccinesPending approval, Moderna (NASDAQ:MRNA)'s updated...
Investing.com -- Stocks in focus in premarket trade on Monday, June 26th. Please refresh for updates. Tesla (NASDAQ:TSLA) stock fell 1.4% after Goldman Sachs downgraded its stance on the EV...
UBS analysts upgraded Moderna (NASDAQ:MRNA) shares to Buy from Neutral with the price target of $191 per share (down from the prior $221). They argue that Moderna offers much more than...
Here is your Pro Recap of the biggest analyst picks you may have missed since Friday: upgrades at |Moderna, Wayfair, Sherwin-Williams, and Sotera Health.InvestingPro subscribers got this...
An analyst from UBS upgraded Moderna (NASDAQ: MRNA) from 'neutral' to 'buy' with a price target of $191.00 from a prior price target of %currency%%price%. Prior to this rating, Moderna...
Preliminary clinical data demonstrated a robust immune response by the company's XBB.1.5 monovalent vaccine against XBB descendent lineage virusesPending authorization, Moderna...
FDA Advisers Back Updating Covid Shots To Target XBB Subvariant - Bloomberg
An analyst from Goldman Sachs maintained Moderna (NASDAQ: MRNA) at 'buy' with a price target of $299.00. Prior to this rating, Moderna had 12 buy ratings, 9 hold ratings, and 1 sell...
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA aloneThe...
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacementTo date, mRNA-3927 has been generally well-tolerated at the doses administered, with...
A Morgan Stanley analyst maintained Moderna (NASDAQ: MRNA) at Equalweight and a price target of $153.00 from a prior price target of %currency%%price%. Prior to this rating, Moderna had 11...
Moderna (MRNA) has filed mixed shelf of:Common StockPreferred StockDebt SecuritiesWarrantsUnits
Moderna (NASDAQ:MRNA) shares opened higher Thursday on the back of its surprising earnings and revenue beat. The drugmaker had been expected to post a $1.75 loss in the quarter, however,...
Investing.com -- Stocks in focus in premarket trade on Thursday, May 4th. Please refresh for updates. PacWest Bancorp (NASDAQ:PACW) stock fell 40% after the regional lender confirmed...
Investing.com -- U.S. stocks are seen opening in a subdued fashion Thursday as investors digest the Federal Reserve’s latest policy move as well as more turmoil in the banking...
Investing.com - Moderna (NASDAQ: MRNA) reported first quarter EPS of $0.19, $1.94 better than the analyst estimate of $-1.75. Revenue for the quarter came in at $1.9B versus the consensus...
Investing.com - U.S. stock futures were trading lower during Wednesday's evening deals, after major benchmark indices extended declines during the regular session, with Federal Reserve...
After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the...
The Enterprise Solutions Hub in the Philippines will support the Asia Pacific region and complements Moderna (NASDAQ:MRNA)'s Enterprise Solutions Hubs in Warsaw, Poland, and Atlanta,...
Investing.com -- First Republic Bank has been taken over by Californian authorities with JPMorgan Chase assuming its deposits, at the start of a week that includes a Federal Reserve meeting,...
Investing.com -- Wednesday's Federal Reserve decision is set to be the highlight of the week, with the central bank expected to announce another quarter point rate hike. A barrage of...
A Guggenheim analyst initiated new coverage Moderna (NASDAQ: MRNA) Neutral rating and a price target of $No data. Prior to this rating, Moderna had 11 buy ratings, 8 hold ratings, and 1...
By Yasin Ebrahim Investing.com -- The Dow pared some losses Thursday, but ended lower as Tesla led a slew of mostly disappointing quarter results just as economic data stoked further worries...
By Yasin Ebrahim Investing.com -- The S&P 500 slipped Wednesday as investor sentiment was soured by disappointing quarterly results including from Tesla and economic data pointing to a...
Moderna invests in developing quantum computing skills and exploring the use of quantum computing in developing future mRNA medicinesModerna, Inc. (Nasdaq: MRNA), a biotechnology company...
Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna (NASDAQ:MRNA) and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, April 17th. Please refresh for updates. Merck (NS:PROR) (NYSE:MRK) stock fell 0.1% after the drugs giant...
By Senad Karaahmetovic Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) announced the results of a closely-watched Phase 2b personalized cancer vaccine (PCV) trial for melanoma. The results...
Moderna, Inc. (Nasdaq: MRNA) and Merck (MRK) announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an...
By Sam Boughedda BofA was left with more questions than answers following Moderna 's (NASDAQ:MRNA) Vaccines Day, BofA analysts told investors in a note Wednesday. The analysts, who have...
A BofA Securities analyst maintained Moderna (NASDAQ: MRNA) at Neutral and a price target of $200.00. Prior to this rating, Moderna had 11 buy ratings, 8 hold ratings, and 1 sell...
By Yasin Ebrahim Investing.com -- The Dow closed higher Tuesday, driven by cyclical corners of the market including energy and financial stocks, though investor sentiment remained cautious...
By Liz Moyer Investing.com -- Stocks are mixed on Tuesday as investors weigh the odds of the Federal Reserve raising interest rates again in May. Here are the market movers for April 11. ...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.